Hikal Limited

HIKAL NSE Healthcare Pharmaceuticals
₹224.95
-4.19%
Delayed · cached 15 min

Fair value analysis

HIKAL
Hikal Limited
HealthcarePharmaceuticals
₹234.78
Close used for this calculation
₹244.29Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
24/100
Profitability2/25
Returns6/25
Balance Sheet14/25
Efficiency2/25
Growth2/25
Weak
Quality radar
24Prof.2/25Ret.6/25Eff.2/25B.Sht14/25Growth2/25

Consensus fair value

₹244.29
Near FV
▲ +4.1% against the close used
Model range ₹21.44 – ₹267.11
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹21.44Fair value₹244.29Bull₹267.11
FairClose
52-week traded range
52W low ₹147.0852W high ₹269.80

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading close to the consensus fair value

Hikal Limited closed at ₹234.78, 3.9% below the consensus fair value of ₹244.29 drawn from 3 valuation models.

Financial DNA score 24/100 — Weak. P/E of 65.4x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₹244.29
+4.1%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
EV/EBITDA
₹267.11
+13.8%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=3.84B
Book Value (P/B)
₹21.44
-90.9%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=97.02, ROE=2.2%, g=3%, r=10%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.